NEW YORK, April 21, 2017 /PRNewswire/ --
On Thursday, April 20, 2017, US markets sawbroad based gains with eight out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,916.78, up 0.92%; the Dow Jones Industrial Average
San Diego, California headquartered Conatus Pharmaceuticals Inc.'s stock advanced 5.87%, to close the day at $7.58. The stock recorded a trading volume of 762,405 shares, which was above its three months average volume of 582,400 shares. Conatus Pharma's shares have rallied 71.49% in the last one month, 66.96% in the previous three months and 166.90% in the past one year. The Company's shares are trading 43.96% and 133.99% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which focuses on the development and commercialization of novel medicines to treat liver diseases in the US, have a Relative Strength Index (RSI) of 73.65. Visit us today and download your complete report on CNAT for free at:
On Thursday, shares in Barcelona, Spain headquartered Grifols S.A. ended the session flat at $19.82 with a total volume of 853,962 shares traded. Grifols' shares have gained 14.63% in the last one month and 17.77% in the previous three months. Furthermore, the stock has gained 30.90% in the past one year. Shares of the Company, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, are trading at a PE ratio of 46.53. The stock is trading 9.82% above its 50-day moving average and 20.57% above its 200-day moving average. Moreover, the Company's shares have an RSI of 73.28. The complimentary research report on GRFS can be accessed at:
On Thursday, shares in Leawood, Kansas headquartered Aratana Therapeutics Inc. recorded a trading volume of 297,605 shares. The stock ended the day 1.21% higher at $5.87. Aratana Therapeutics' stock has gained 15.78% in the past one month. The Company's shares are trading below its 50-day and 200-day moving averages by 0.84% and 22.65%, respectively. Furthermore, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the US and Belgium, have an RSI of 60.03. Register for free on Stock-Callers.com and download the PDF research report on PETX at:
Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc.'s stock finished Thursday's session 0.94% lower at $48.28 with a total volume of 983,245 shares traded. Agios Pharma's shares have gained 14.87% in the past three months. The Company's shares are trading below its 50-day and 200-day moving averages by 6.88% and 0.10%, respectively. Shares of Agios Pharma, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 33.93. Get free access to your research report on AGIO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Do fad diets really work? Here are some disadvantages and side-effects of going on a fad diet. ...
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...